Literature DB >> 17061154

Atypical carcinoid tumor of the thymus with ectopic ACTH production developed during the course of etanercept treatment--case report.

Ismail Simsek1, Salih Pay, Ayhan Dinc, Hakan Erdem, Bulent Kurt.   

Abstract

Ever since the introduction of anti-tumor necrosis factor (TNF) agents, concerns have been raised regarding their potential for developing malignancy. We report the development of thymic atypical carcinoid tumor 9 months after the initiation of etanercept therapy in a patient having refractory spondylarthritis. This case indicates the need for following large cohorts of patients receiving anti-TNF agents to address the long-term effect of these agents on malignancies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17061154     DOI: 10.1007/s10067-006-0454-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  8 in total

1.  Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.

Authors:  S Lori Brown; Mark H Greene; Sharon K Gershon; Evelyne T Edwards; M Miles Braun
Journal:  Arthritis Rheum       Date:  2002-12

2.  Acute myelogenous leukaemia following etanercept therapy.

Authors:  G Bakland; H Nossent
Journal:  Rheumatology (Oxford)       Date:  2003-07       Impact factor: 7.580

3.  Crohn's colitis presenting with node-negative colon cancer and liver metastasis after therapy with infliximab: report of two cases.

Authors:  Thomas Nicholson; Guy R Orangio; David Brandenburg; Douglas C Wolf; E Earl Pennington
Journal:  Dis Colon Rectum       Date:  2005-08       Impact factor: 4.585

4.  Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab.

Authors:  Jan Brandt; Hildrun Haibel; Jaqueline Reddig; Joachim Sieper; Jürgen Braun
Journal:  J Rheumatol       Date:  2002-01       Impact factor: 4.666

5.  Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.

Authors:  P Geborek; A Bladström; C Turesson; A Gulfe; I F Petersson; T Saxne; H Olsson; L T H Jacobsson
Journal:  Ann Rheum Dis       Date:  2005-02-04       Impact factor: 19.103

6.  A clinicopathologic study of 12 neuroendocrine tumors arising in the thymus.

Authors:  Olivier Tiffet; Andrew G Nicholson; Georges Ladas; Mary N Sheppard; Peter Goldstraw
Journal:  Chest       Date:  2003-07       Impact factor: 9.410

7.  Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab.

Authors:  Adam C Esser; Andy Abril; Scott Fayne; John A Doyle
Journal:  J Am Acad Dermatol       Date:  2004-05       Impact factor: 11.527

Review 8.  Safety of tumour necrosis factor-alpha antagonists.

Authors:  Dinesh Khanna; Maureen McMahon; Daniel E Furst
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

  8 in total
  2 in total

1.  Clinicopathological analysis of 21 thymic neuroendocrine tumors.

Authors:  Soomin Ahn; Jae Jun Lee; Sang Yun Ha; Chang Ohk Sung; Jhingook Kim; Joungho Han
Journal:  Korean J Pathol       Date:  2012-06-22

Review 2.  Ectopic Cushing's syndrome due to thymic neuroendocrine tumours: a systematic review.

Authors:  Fernando Guerrero-Pérez; Inmaculada Peiró; Agustina Pia Marengo; Alex Teulé; José Carlos Ruffinelli; Roger Llatjos; Teresa Serrano; Ivan Macia; Nuria Vilarrasa; Pedro Iglesias; Carles Villabona
Journal:  Rev Endocr Metab Disord       Date:  2021-05-07       Impact factor: 6.514

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.